Roche's Hemophilia Drug Shows Hemostatic Normalization Potential in Early-stage Study
Published on 06/23/2025 at 06:33 am BST
MT Newswires
Share
Share
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 327.70 CHF | -0.55% |
|
+2.49% | +0.37% |
Employees
103,249
Sector
Pharmaceuticals
Calendar
07-23 -
Earnings release - Q2 2026
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
AA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
329.50CHF
Average target price
360.76CHF
Spread / Average Target
+9.49%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROP Stock
- ROG Stock
- News Roche Holding AG
- Roche's Hemophilia Drug Shows Hemostatic Normalization Potential in Early-stage Study
Select your edition
All financial news and data tailored to specific country editions
